Hot Features
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye dise... OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.19 | -10.9826589595 | 1.73 | 1.76 | 1.54 | 46851 | 1.6552013 | CS |
| 4 | -0.1 | -6.09756097561 | 1.64 | 1.76 | 1.54 | 46953 | 1.65063641 | CS |
| 12 | -0.14 | -8.33333333333 | 1.68 | 1.76 | 1.44 | 71562 | 1.60641864 | CS |
| 26 | -0.39 | -20.207253886 | 1.93 | 3.2 | 1.44 | 169602 | 1.96210962 | CS |
| 52 | -0.31 | -16.7567567568 | 1.85 | 3.349 | 1.44 | 164010 | 2.20000975 | CS |
| 156 | 0.21 | 15.7894736842 | 1.33 | 3.349 | 0.8075 | 146518 | 1.87588835 | CS |
| 260 | -2.96 | -65.7777777778 | 4.5 | 7 | 0.8075 | 160636 | 2.18048255 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.